Introduction {#s1}
============

Relapsing-remitting multiple sclerosis (RRMS) is a severe inflammatory degenerative disease of the central nervous system (CNS), with typical onset occurring in the third to fourth decade of life ([@B1]). While its etiology is not defined, autoimmunity (influenced by environmental and genetic factors) is still considered a major player in the disease etiopathogenesis ([@B1]).

RRMS shows a three times higher disease prevalence in women than men but causes disability faster in men ([@B1]). It has been suggested that the gender dimorphism may be linked to the effects of sex hormones on the immune system and parenchymal CNS cells. Indeed, the modifications of sexual hormone milieu in women at puberty, during pregnancy, puerperium, and after menopause may significantly modify the course of RRMS ([@B2]).

In men, 98% of plasmatic testosterone (T) is irreversibly converted to the active metabolite 5α-dihydrotestosterone (5α-DHT), which binds the androgen receptor with a higher affinity than T. 5α-DHT is a DNA-binding ligand-activated transcription factor that regulates the expression of the target gene in many cell lines, including leukocytes ([@B3], [@B4]). There are several important effects of T on immune function, such as the shift from the Th1 to Th2 phenotype, leading to an increased production of interleukin-5 (IL-5) and interleukin-10 (IL-10) and decreased pro-inflammatory cytokines such as interferon-(IFL- γ), tumor necrosis factor-α (TNF-α), and interleukin-17 (IL-17), with a consequent impact on lymphocyte proliferation and differentiation. Several studies have described the neuroprotective effect of T, given its ability to cross the blood--brain barrier and directly act on neuronal cells ([@B5], [@B6]).

In patients with MS, a relative androgen deficiency has been suggested and lower levels of T were correlated with disability severity and decreased cognitive function. In one pilot study, 10 men with MS were treated with 10 g of T gel (100 mg) in a cross-over design (6-months of observation followed by 12 months of treatment), demonstrating a significant slowing of brain atrophy measured from monthly magnetic resonance imaging (MRI) and improvement in cognitive testing ([@B7]).

Less investigated has been the activity of hypothalamus-pituitary-testicular (HPT) axis and sperm parameters in patients with MS ([@B7]). Neuroinflammation can disrupt this axis, with consequences on hormone production and reproductive function; therefore, this topic needs to be more deeply evaluated. Recent public health announcements consider semen quality as an index of general health, further suggesting the need for this to be evaluated in men with MS.

The current case-controlled prospective pilot study was designed to evaluate gonadal steroids and sperm parameters of men at both onset of RRMS and 12 months following their first disease modifying treatment (DMT).

Methods {#s2}
=======

Participants
------------

This is a prospective case-control pilot study, conducted at the tertiary MS Center of Catania, the main referral center in Eastern Sicily (Italy), with a wide catchment area including the regional areas of Catania, Syracuse, Enna, and Ragusa (with more than 2,000,000 inhabitants). Patients with RRMS who were admitted to the MS Center from February 1st to August 31st, 2018 were screened according to the following criteria:

Inclusion Criteria

\(a\) male gender; (b) age between 18 and 55 years; (c) a definitive diagnosis of RRMS per revised McDonald criteria ([@B8]); and (d) have not been exposed to any DMT.

Exclusion Criteria

\(a\) history of any known disease which can cause endocrine abnormalities (e.g., diabetes, other autoimmunity diseases, etc.) except hypogonadism; and (b) diagnosis of alcohol and/or drug dependence.

Patients were prospectively followed over 12 months and then re-evaluated. Controls were men with normal evaluation screened for gonadal steroids and sperm parameters who acceded to the Andrology Center of Catania in a contemporary matched randomized fashion (for age and Body Mass Index, BMI) to the group of RRMS patients.

Protocol Approvals Standard, Registrations, and Patient Consents
----------------------------------------------------------------

The local ethics committee (Comitato Etico Catania 1, n. 0011849/2019) at Policlinico Vittorio Emanuele, Catania, Italy approved the study protocol. Subjects with RRMS provided written informed consent. The current study was conducted in accordance with the ethical principles of the Declaration of Helsinki as well as with the appropriate national regulations.

Data Collection and Definitions
-------------------------------

Subjects with RRMS were evaluated for neurological and andrological status both at enrollment and 12 months following the start of the prescribed DMTs.

Neurological Assessment
-----------------------

The following data were collected from each subject:

-   *Demographic data*. Data collected included date of birth, BMI, smoking status, and number of children the subject had fathered.

-   *Clinical data*. Included the date of MS onset, type of MS, and level of disability as assessed by the Expanded Disability Status Scale (EDSS). Symptoms at onset were classified as involving supratentorial, visual pathway, cerebellar/brainstem, and spinal cord symptoms.

-   *Radiological data*. The scanning sessions of the brain and spinal MRI sequences were T1- and T2-weighted sequences acquired only with 1.5 Tesla scanners and longitudinally with the same scanner. Spinal cord MRI included both cervical and thoracic tracts.

    The T1-weighted sequences were acquired before and after intravenous injection of gadolinium contrast agent (0.1 mmol/kg).

    A cerebral and spinal cord MRI acquired within 3 months before or 1 week after the treatment start was considered as a baseline MRI.

    The numbers of brain and spinal (cervical and thoracic) MRI lesions on T2-weighted and post-contrast T1-weighted sequences were recorded at baseline and after 12-month of follow-up from the beginning of DMT.

    Lesions and imaging were compared with the support of available software (Carestream®Healthcare Information Systems software).
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-   *Cognitive impairment as evaluated by the Brief Repeatable Battery Neuropsychology (BRB-N) and Stroop test*. BRB-N evaluation included Selective Reminding Test Long-Term Storage, Selective Reminding Test Long-Term Retrieval, Selective Reminding Test Delayed Recall, 10/36 Spatial Recall Test, 10/36 Spatial Recall Test Delayed, Symbol Digit Modalities Test (SDMT), Paced Auditory Serial Addition Task 3 (PASAT 3), and Word List Generation (WLG) ([@B9], [@B10]). Also, Stroop Test was performed. Patients were classified as having cognitive impairment when they fail at least three neuropsychological tests belonging to the BRB ([@B11]) and Stroop test, in the light of previous studies using the same neuropsychological battery and reporting that less than 5% of healthy controls failed more than three tests ([@B10], [@B12], [@B13]).

-   *First prescribed DMT*. Included the type of DMT, start date and any withdrawn or switch date.

    All neurological evaluations were performed by neurologists (ED, AZ, FP) trained in neurostatus examinations (<https://www.neurostatus.net>). Data were retrieved from a computerized database, iMed^©^ software (iMed^©^, Merck Serono SA; Geneva) in accordance with the Italian MS Web registry guidelines.

Andrological Assessment
-----------------------

The andrological assessment was conducted in the Division of Andrology and Endocrinology at the University of Catania. Each patient underwent the following blood testing and laboratory/instrumental tests:

-   *Hormonal Measurements*. Blood sampling was performed at 8.00--8.30 am, after at least 8 h of sleep. The serum concentrations of luteinizing hormone (LH), Follicle-stimulating hormone (FSH), and total testosterone (TT) were measured by electrochemiluminescence using a Hitachi-Roche equipment (Cobas 6000, Roche Diagnostics, Indianapolis, IN, USA). Normal ranges were defined as LH = 1.6--9.0 mIU/mL^−1^, FSH = 2.0--12.0 mIU/mL^−1^, TT = 3.5--8.0 ng/mL^−1^ (the gray-zone for TT was defined 2.3--3.4 ng/mL^−1^). The blood tests also included a complete blood count and differential, platelet count, sex hormone binding globulin (SHBG), albumin, aspartate, and alanine aminotransferase, alkaline phosphatase, total bilirubin, creatinine, and electrolytes. Free T (fT) was calculated using the serum values of TT, SHBG and albumin.

-   *Sperm analysis*. Seminal fluid samples were collected by masturbation in a sterile container following 2--7 days of sexual abstinence and were transported to the laboratory within 30 min from ejaculation. Sperm analysis was performed according to the 2010 WHO criteria ([Appendix 1](#SM1){ref-type="supplementary-material"}).

Hypogonadism was defined using the latest definition proposed by the Endocrine Society guidelines ([@B14]).

Outcomes {#s3}
========

The main objectives of the study were to identify any correlation between disease characteristics at onset and hormonal/sperm parameters and investigate if hormonal/sperm parameters were associated with longitudinal changes of clinical/radiological parameters 12 months following the first prescribed DMT.

Statistical Analysis and Covariate Definitions
----------------------------------------------

Baseline characteristics and gonadal steroids are reported as frequencies (%), mean with standard deviation, or median with interquartile range (min-max). Sperm parameters were calculated assuming a binomial distribution with 95% confidence intervals. Proportions among categorical variables were compared using a χ^2^ analysis.

To examine the associations between androgen measures and other hormones, Pearson correlation coefficients and partial Pearson correlation coefficients adjusting for age and BMI were calculated. The primary cross-sectional analysis was the correlation between total testosterone, free T, and EDSS at the first visit date. Secondarily, the cross-sectional correlation between total testosterone and number of relapses in the year prior to diagnosis and number of brain MRI lesions on T2 and T1 gadolinium weighted sequences were investigated. Exploratory analyses were run for the other androgen variables (free testosterone, SHBG, and sperm parameters) using similar models. A 2-tailed *p*-value of lower than 0.05 was considered significant.

The longitudinal analyses examined the association between baseline testosterone levels and longitudinal changes in clinical and radiological parameters using generalized estimating equations.

According to the AIC criterium, we selected the model with the best statistical inferential properties. All the models were estimated using the Breslow\'s tie correction.

For each outcome and predictor pair, the mean change in each outcome was assumed to be linear with time and the primary analysis was the effect of the baseline testosterone measurement on the change over time. Each model was fit assuming an identity link function and an exchangeable working correlation structure. Robust standard errors were used to calculate *p*-values ([@B15]). Each model was corrected for: age (as continuous variable), BMI (as continuous variable), time from first symptom to diagnosis (disease duration, in months, continuous variable) and line of DMT prescribed (as categorical variable).

These models were conducted for the following outcomes: EDSS (at baseline and after 12 months from enrolment), number of brain MRI lesions on T2 weighted sequences (at baseline and after 12 months from enrolment), number of brain MRI lesions on T1-gadolinium weighted sequences (at baseline and after 12 months from enrolment), and for number of relapses (within 12 months before diagnosis and after 12 months from enrolment). They were built using the proportional odds link and conclusions were the same as those reported below.

The formula employed for sample size calculation was sample size value for finite population. Giving annual incidence of RRMS in Catania and total population in province of Catania (ISTAT), setting a pre-study standard deviation to 50% because the behavior of the population under study is not known (pilot-study), with a Z-score of 1.96 and margin of error (e) of 0.05 and considering 6 months of enrolment, the population of the study will have to reach 26.

SPSS version 21.0 was used for all analyses (IBM SPSS Statistics 21, IBM^©^, Armonk, NY, USA).

Data Availability Statement {#s4}
===========================

Anonymized data will be shared upon request from any qualified investigator for the sole purpose of replicating procedures and results presented in the current report, provided that the data transfer is in agreement with EU legislation on the general data protection regulation.

Results {#s5}
=======

Out of 41 screened patients, 38 were enrolled in the current study with three excluded due to non-consent of participation ([Figure 1](#F1){ref-type="fig"}). The mean age of the 38 patients enrolled was 40.3 ± 12.3 years old and the median EDSS score was 1.5 (IQR 1.0--2.0). Fifteen patients were childless and out of them, twelve did not desire offspring at the time of enrolment. [Table 1](#T1){ref-type="table"} summarizes other relevant demographic and clinical characteristics.

![Patients\' selection flow chart. RRMS, relapsing remitting multiple sclerosis.](fneur-11-00756-g0001){#F1}

###### 

Demographic and clinical characteristics at enrolment.

  **Variables[^\*^](#TN1){ref-type="table-fn"}**                   
  ---------------------------------------------------------------- --------------
  Age                                                              40.3 ± 12.3
  Smokers, n (%)                                                   22 (57.9)
  BMI                                                              23.7 ± 2.1
  Men childless                                                    15 (39.5)
  EDSS (median, IQR)                                               1.5 (1--2.0)
  Time from first symptoms (disease duration, months)              11.8 ± 6.4
  N. of relapse 2 years before diagnosis                           1.4 ± 1.3
  N. of relapse 1 year before diagnosis                            1.3 ± 0.6
  Type of onset, n (%)                                             
  *Visual*                                                         2 (5.4)
  *Spinal*                                                         6 (16.2)
  *Pyramidal*                                                      0
  *Cerebellar*                                                     0
  *Multidomain*                                                    29 (78.4)
  N. brain MRI lesions on T2-weighted sequences                    16 ± 11.2
  N. spinal cord MRI lesions on T2-weighted sequences              3.0 ± 2.3
  N. brain MRI lesions on T1-gadolinium weighted sequences         0.4 ± 0.9
  N. spinal cord MRI lesions on T1-gadolinium weighted sequences   0.5 ± 0.8
  Patients with cognitive impairment at enrollment, n (%)          7 (5.4)
  Number of impaired tests at BRB                                  0.7 ± 0.8

*BMI, body mass index; BRB, brief repeatble battery; EDSS, expanded disability status scale; IQR, interquartile range; MRI, magnetic resonance imaging; N, number*.

*Data are expressed as mean ± standard deviation when otherwise specified*.

Hormonal Assessment and Sperm Parameters
----------------------------------------

The median values of TT and calculated free-T are shown in [Table 2](#T2){ref-type="table"}. Among the RRMS patients, 3 (7.9%) patients had hypogonadism with no compensatory elevation of LH and 5 (13.2%) patients were in the gray zone. Patients with RRMS showed no differences in fT values, while fT was higher in healthy controls (*p* \< 0.001). Among controls, hypogonadism was present in three patients (7.9%) and eight were in the gray zone (21.1%). Patients with RRMS, compared to healthy controls (according to WHO 2010 reference values), did not show any differences in terms of seminal fluid volume, total sperm count, or total and progressive motility ([Table 2](#T2){ref-type="table"}).

###### 

Hormonal assessment and spermatic parameters in RRMS patients at enrolment and in an age-BMI matched control population.

  **Variables[^\*^](#TN2){ref-type="table-fn"}**   **Cases**               **Controls**          ***p*-value**
  ------------------------------------------------ ----------------------- --------------------- ------------------------------------------------
  **Hormonal parameters**                                                                        
  TT                                               4.8 (3.4--6.2)          5.3 (4.4--6.6)        ns
  **freeT**                                        **0.09 (0.07--0.11)**   **1.4 (0.9--1.91)**   ***0.000[^\*\*^](#TN3){ref-type="table-fn"}***
  FSH                                              3.8 (2.4--5.9)          3.6 (2.3--4.1)        ns
  LH                                               3.3 (2.3--4.5)          3.1 (2.3--4.1)        ns
  SHBG                                             32.4 (27.4--43.4)       32.5 (26.1--41.7)     ns
  **Spermatic parameters**                                                                       
  Total number                                     179.3 ± 165.7           196.8 ± 129.6         ns
  Concentration                                    59.4 ± 44.6             74.5 ± 37.6           ns
  Volume                                           3.2 ± 1.7               2.6 ± 1.2             ns
  Morphology                                       6.3 ± 3.5               7.2 ± 4.4             ns
  Progressive motility                             18.0 ± 10.6             19.4 ± 12.6           ns

*Data are expressed as mean ± standard deviation and as median (IQR)*.

*significant p-values are in bold*.

*BMI, body mass index; IQR, interquartile range; FSH, follicular stimulant hormone; LH, luteinizing hormone; N, number; SHBG, sex hormone binding globulin; TT, total testosterone; freeT, free testosterone*.

DMT\'s Prescription
-------------------

All RRMS patients started a DMT within 3 months from onset and none discontinued treatment prior to the last follow-up ([Figure 2](#F2){ref-type="fig"}). No differences were found about the rate of first and second line DMTs prescribed: 20/38 (52.6%) RRMS patients were on first line DMT, whilst 18/38 (47.4%) were on second line DMT.

![First DMT prescribed. DMT, disease modifying therapy.](fneur-11-00756-g0002){#F2}

Cross-Sectional Analyses
------------------------

The correlation analyses between gonadal steroids/sperm parameters and disease characteristics at onset (see methods) showed no primary correlation alone nor when corrected for age and BMI (see [Tables 3A](#T3A){ref-type="table"},[B](#T3B){ref-type="table"}).

###### 

Association between baseline androgens and baseline clinical (EDSS. number of relapses 12 months before diagnosis), baseline radiological (N. MRI T2 and T1-gadolium weighted lesions) and n. of impaired tests cross-sectional outcomes.

  **Cross-sectional**                                                                                               
  --------------------------------------------- -------------- ---------------- -------------------------- -------- ---------
                                                               **Unadjusted**   **Age and BMI adjusted**            
                                                **Hormone**    **R**            ***p***                    **R**    ***p***
  EDSS                                          Testosterone   0.094            0.694                      0.133    0.612
                                                freeT          0.042            0.859                      0.087    0.739
  N. brain MRI T2-weighted lesions              Testosterone   −0.208           0.250                      −0.184   0.013
                                                freeT          −0.174           0.333                      0.480    0.961
  N. brain MRI T1-gadolinium weighted lesions   Testosterone   0.021            0.909                      −0.080   0.762
                                                freeT          −0.040           0.824                      0.005    0.986
  N. of relapses 12 months before diagnosis     Testosterone   −0.141           0.441                      −0.155   0.553
                                                freeT          −0.103           0.573                      −0.103   0.693
  N. of cognitive tests impaired                Testosterone   −0.345           0.091                      −0.280   −0.243
                                                freeT          −0.344           0.092                      0.195    0.264

*EDSS, expanded disability status scale; Gad, gadolinium; N, number; MRI, magnetic resonance imaging*.

*For the EDSS correlations, Spearman\'s correlation coefficients are reported; for the others, Pearson\'s correlation coefficients are reported*.

###### 

Association between baseline sperm parameters and baseline clinical (EDSS. number of relapses 12 months before diagnosis), baseline radiological (N. MRI T2 and T1-gadolium weighted lesions) and cognitive (number of impaired tests) cross-sectional outcomes.

  **Cross-sectional**                                                                                                      
  --------------------------------------------- --------------------- ---------------- -------------------------- -------- ---------
                                                                      **Unadjusted**   **Age and BMI adjusted**            
                                                **Sperm parameter**   **R**            ***p***                    **R**    ***P***
  EDSS                                          Volume (ml)           −0.093           0.862                      0.054    0.815
                                                Count (10^6^/ml)      0.165            0.474                      0.000    1
                                                Total count (10^6^)   0.035            0.880                      0.225    0.326
                                                Motility (%)          −0.292           0.199                      −0.275   0.227
                                                Progressive (%)       0.020            0.933                      0.035    0.882
                                                Morphology (%)        0.231            0.314                      0.157    0.496
  N. brain MRI T2-weighted lesions              Volume (ml)           −0.260           0.223                      −0.230   0.323
                                                Count (10^6^/ml)      0.132            0.457                      −0.411   0.136
                                                Total count (10^6^)   0.132            0.458                      −0.235   0.271
                                                Motility (%)          0.132            0.457                      0.008    0.491
                                                Progressive (%)       0.022            0.901                      0.210    0.293
                                                Morphology (%)        0.214            0.225                      0.412    0.135
  N. brain MRI T1-gadolinium weighted lesions   Volume (ml)           0.103            0.561                      −0.203   0.200
                                                Count (10^6^/ml)      0.103            0.561                      0.396    0.146
                                                Total count (10^6^)   0.157            0.374                      −0.235   0.271
                                                Motility (%)          0.224            0.203                      0.008    0.491
                                                Progressive (%)       0.097            0.587                      0.210    0.293
                                                Morphology (%)        0.047            0.792                      0.412    0.135
  N. of relapses 12 months before diagnosis     Volume (ml)           0.127            0.482                      0.049    0.450
                                                Count (10^6^/ml)      0.162            0.366                      −0.186   0.316
                                                Total count (10^6^)   −0.125           0.714                      −0.329   0.194
                                                Motility (%)          0.035            0.845                      −0.092   0.407
                                                Progressive (%)       −0.147           0.414                      0.126    0.373
                                                Morphology (%)        0.155            0.390                      −0.541   0.066
  N. of cognitive tests impaired                Volume (ml)           −0.058           0.881                      0.485    0.135
                                                Count (10^6^/ml)      −0.236           0.218                      0.035    0.470
                                                Total count (10^6^)   −0.086           0.656                      0.556    0.097
                                                Motility (%)          −0.149           0.442                      0.406    0.183
                                                Progressive (%)       −0.253           0.185                      0.437    0.163
                                                Morphology (%)        −0.105           0.588                      0.613    0.072

*EDSS, expanded disability status scale; Gad, gadolinium; N, number; MRI, magnetic resonance imaging*.

*For the EDSS correlations. Spearman\'s correlation coefficients are reported*.

Longitudinal Analyses-12-Months Follow-Up
-----------------------------------------

Following 12 months, no differences were found in either gonadal steroids or sperm parameters in the current cohort ([Table 4](#T4){ref-type="table"}). Additionally, our analyses assessing the relationship between baseline TT and longitudinal clinical changes (EDSS, MRI lesions load, and relapses) demonstrated no associations ([Table 5](#T5){ref-type="table"}).

###### 

Hormonal assessment and spermatic parameters in RRMS patients at enrolment and after 12 months.

  **Variables[^\*^](#TN4){ref-type="table-fn"}**   **AT Enrolment**    **After 12 months**   ***p*-value**
  ------------------------------------------------ ------------------- --------------------- ---------------
  **Hormonal parameters**                                                                    
  TT                                               4.8 (3.4--6.2)      5.1 (3.9--6.7)        ns
  freeT                                            0.09 (0.07--0.11)   0.09 (0.07--0.11)     
  FSH                                              3.8 (2.4--5.9)      2.9 (2.1--4.1)        ns
  LH                                               3.3 (2.45)          2.7 (1.7--3.2)        ns
  SHBG                                             32.4 (27.4--43.4)   36.4 (30.4--48.9)     ns
  **Spermatic parameters**                                                                   
  Total number                                     179.3 ± 165.7       129 ± 127.4           ns
  Concentration(10^6^/ml)                          59.4 ± 44.6         50 ± 37               ns
  Volume (ml)                                      3.2 ± 1.7           3 ± 1.7               ns
  Morphology (%)                                   6.3 ± 3.5           6.5 ± 3.6             ns
  Total motility (%)                               70 ± 49.5           70 ± 51.1             ns
  Progressive motility (%)                         18.0 ± 10.6         20.7 ± 10.3           ns

*Data are expressed as mean ± standard deviation and as median (IQR)*.

*IQR, interquartile range; FSH, follicular stimulant hormone; LH, luteinizing hormone; N, number; SHBG, sex hormone binding globulin, TT, total testosterone; freeT, free testosterone*.

###### 

Association between androgen levels and longitudinal changes in clinical and radiological outcomes.

  **Longitudinal changes**                                                                                            
  ------------------------------------------------------ -------------- ---------------- ------------ --------------- -------
                                                         **Hormone**    ***Estimate***   **95% CI**   ***p-value***   
                                                                                         **Lower**    **Upper**       
  EDSS                                                   Testosterone   0.035            −0.128       −0.199          0.673
                                                         FreeT          0.240            −2.25        2.73            0.850
  Relapses                                               Testosterone   0.206            −0.494       0.906           0.564
                                                         FreeT          3.76             −21.88       29.41           0.774
  Lesions load at MRI T2-weighted sequences              Testosterone   −0.144           −3.16        0.271           0.099
                                                         FreeT          −13.7            −44.27       16.7            0.376
  Lesions load at MRI T1-gadolinium weighted sequences   Testosterone   0.197            −0.320       0.807           0.498
                                                         FreeT          3.12             −19.76       18.96           0.633

*GEE analysis for the yearly changes in EDSS, MRI lesions load and relapses for 100 unit of increase of baseline TT*.

*freeT, free testosterone; GEE, generalized estimation equation; MRI, magnetic resonance imaging; TT, total testosterone*.

Discussion {#s6}
==========

In the current cohort, patients with RRMS showed a prevalence of hypogonadism comparable to data reported in population-based studies, in which the prevalence of male hypogonadism is described from 2.1 to 12.8% ([@B16]). Furthermore, sperm parameters did not differ from controls. There was no change in gonadal steroids or sperm parameters after 12 months from the first prescribed DMT nor were clinical and radiological variables at last follow-up associated with baseline gonadal steroids and sperm parameters.

Very limited data are available on this topic and, to date, no prospective studies have been performed.

The role of T in influencing MS onset and course is matter of debate. In studies on autoimmune diseases such as systemic lupus erythematosus or rheumatoid arthritis, it has been suggested that low testosterone levels may be present at disease onset.

In a recent observational study on 96 men with RRMS (mean age of 40 years, EDSS of 1.1, and disease duration of 4.6 years), that 39% were hypogonadal (total testosterone \<288 ng/dl), demonstrating an association of low baseline TT levels and disease severity ([@B11], [@B17]). The frequency of MS in men is three times less than in women, however, they are more prone to develop severe disability, recover poorly from relapses, and experience increased rates of brain atrophy ([@B18]). Unfortunately, limited data currently exists on the effects of T supplementation in men with MS. In a cross-over pilot study, 10 patients with RRMS (aged \<65 years) received a daily treatment with 100 mg T gel for 12 months ([@B19]). After T treatment, there was a significant improvement in the cognitive performance (*p* = 0.008) as measured by the Paced Auditory Serial Addition Task and a slowing of atrophy, as measured with MRI (*p* \< 0.001). No significant effect of T was found on T1 gadolinium lesion numbers or whole brain volume, however ([@B20]). These data may suggest an immunomodulatory and a potentially neuroprotective effect of T treatment in MS, however, additional large, multicenter studies are needed to confirm these results.

We did not find any differences of sperm quality compared to controls, nor were any associations found with clinical/radiological characteristics at onset. In a cross-sectional study in which a total of 68 patients with MS (mean age 44.2 years, range 31--56 years) were compared to 48 healthy volunteers, Safarinejad et al. ([@B7]) described abnormal sperm parameters in 14 patients with RRMS (out of 66). In another study, 73 patients with MS represented an ancillary subpopulation of 4,480 patients (with cancers and chronic inflammatory diseases) ([@B21]). Of these patients, 27.4% had sperm abnormalities (compared to WHO 2010 reference values) ([@B21]). Given these findings, it is not currently clear if systemic inflammation in MS impacts testicular physiology and sperm production ([@B22]).

The MS therapeutic landscape has impressively changed in the last few years, with very striking and effective drugs being released. The increase in efficacy, however, has been accompanied by an increase in safety concerns. In this regard, no attention has been paid on men\'s fertility status in either research or clinical practice. In the pursuit of a personalized treatment, future studies are needed to clarify the impact of new DMTs on spermatogenesis and male fertility ([@B23], [@B24]).

In summary, the current study finds no specific issues in general male fertility status and that neither gonadal steroids nor sperm quality was associated with disability accrual after 12 months on DMTs, but this short follow up cannot allow definitive conclusions.
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